Parathyroid Cyst Mystery Solved: How Advanced Imaging Finds Hidden Causes of Hyperparathyroidism
"When standard tests fail, a new type of scan unveils a rare cause of elevated parathyroid hormone, leading to successful treatment."
Parathyroid cysts are uncommon, fluid-filled sacs near the parathyroid glands. These cysts rarely cause problems, but sometimes they lead to primary hyperparathyroidism (PHPT), a condition where the parathyroid glands produce too much parathyroid hormone (PTH). Diagnosing these cysts can be tricky because they often don't show up on standard imaging tests.
A new imaging technique, 18F-fluorocholine positron emission tomography/computerized tomography (FC-PET/CT), is showing promise in locating these hidden cysts. This scan is usually used for cancer detection, but recent research suggests it can also pinpoint overactive parathyroid glands that are missed by traditional methods.
This article explores how FC-PET/CT successfully identified a parathyroid cyst in a woman with normocalcemic PHPT (normal calcium levels but high PTH), whose condition was previously undiagnosed. This case highlights the potential of FC-PET/CT in resolving diagnostic challenges and improving patient outcomes.
Incidence and Recognition
A retrospective analysis of the TriNetX Global database covering 1998–2023 assessed the incidence and prevalence of primary hyperparathyroidism (PHPT), excluding renal hyperparathyroidism and other secondary causes of hypercalcemia. It classified PHPT subtypes using serum calcium and parathyroid hormone (PTH) levels; classic PHPT was defined as calcium of at least 10.5 mg/dL. Estimating incidence can be difficult because many people with PHPT are asymptomatic and may not receive further evaluation of hypercalcemia, including PTH measurement. A biochemistry-based definition alongside diagnostic codes can provide a more complete estimate of PHPT incidence.
Early Clinical Milestones
The Viennese Medical School contributed to early clinical understanding of the relationship between the parathyroid glands and bone metabolism. F. Mandl described a patient in 1925, and E. Gold described another in 1927; both had osteitis fibrosa cystica and biochemical findings of hypercalcemia and hypercalciuria. Gold had already used the term primary hyperparathyroidism in 1928. These reports linked the clinical and biochemical features of the disease.
The Case: Unmasking a Hidden Cyst
A 76-year-old woman with osteoporosis experienced worsening bone density despite treatment with bisphosphonates, calcium, and vitamin D. Her calcium levels were normal, but her parathyroid hormone (PTH) levels were elevated. Standard imaging, like sestaMIBI scans, failed to identify any parathyroid abnormalities, which normally indicates cause for elevated PTH.
- Initial Presentation: Worsening osteoporosis despite treatment.
- Biochemical Findings: Normal calcium, elevated PTH.
- Imaging Results: SestaMIBI scans were negative.
- FC-PET/CT Scan: Identified a lesion near the right superior parathyroid gland.
- Surgical Outcome: Removal of the lesion led to resolution of hyperparathyroidism.
Evolving Diagnosis
Primary hyperparathyroidism is characterized by hypercalcemia with elevated or inappropriately normal serum PTH. Diagnosis relies on biochemical testing, including serum calcium and PTH, as well as urine calcium measurement. A 2026 editorial describes a collection of original research and comprehensive reviews focused on evolving approaches to diagnosing parathyroid disease. A broader review characterizes hyperparathyroidism as dysregulated PTH secretion that disrupts calcium and phosphate homeostasis.
A New Era in Parathyroid Imaging
This case highlights the potential of FC-PET/CT in diagnosing parathyroid cysts, especially when standard imaging techniques fail. FC-PET/CT may be useful in localizing parathyroid hyperplasia and ectopic parathyroids, often missed by traditional sestaMIBI scans. Ectopic parathyroids are glands located in unusual places, making them hard to find.
Changing Clinical Patterns
A study of primary hyperparathyroidism notes that clinical features differ between developed and developing countries. It also reports that patterns of the disease have changed over past decades, while large-cohort data from China remain limited. The study sets out to examine clinical features in Chinese patients, reflecting an effort to address that evidence gap. A 2026 review frames hyperparathyroidism through the distinct clinical and biochemical profiles of its primary, secondary, and tertiary forms.
Variable Presentation and Diagnosis
Hyperparathyroidism occurs when one or more parathyroid glands become overactive, raising PTH and potentially causing hypercalcemia. Patients may have no symptoms or may experience issues such as fatigue, body aches, sleep difficulty, bone pain, memory loss, poor concentration, depression, or headaches. Diagnosis depends on interpreting blood tests: Mayo Clinic notes that high PTH together with high blood calcium can support a diagnosis, while many other conditions can also raise blood calcium. The condition includes primary, secondary, and tertiary forms with distinct clinical and biochemical profiles.
While promising, more research is needed to compare FC-PET/CT directly with sestaMIBI scans in patients with PHPT. These studies will help determine the best use of FC-PET/CT in clinical practice. Comparative study will allow researchers to identify the impact of the new technology vs the current gold standard.
FC-PET/CT offers a valuable tool for pinpointing elusive parathyroid cysts, leading to timely surgical intervention and improved outcomes. This technology helps in diagnosing the right root cause and suggest treatment plan for rare diseases or conditions.